Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Albers · SciRah

Researcher profile · Semantic Scholar

F. Albers

Share profile

F. Albers — researcher profile on SciRah

h-index: 29
Works: 127
Citations: 4,279

Most-cited papers

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
I. Pavord, P. Chanez, G. Criner, H. Kerstjens +11 more
2017New England Journal of Medicine553 citations Open access
Semantic Scholar
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
G. Chupp, E. Bradford, F. Albers, D. Bratton +5 more
2017The Lancet Respiratory Medicine543 citations
Semantic Scholar
Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
S. Khatri, W. Moore, P. Gibson, R. Leigh +11 more
2019Journal of Allergy and Clinical Immunology275 citations Open access
Semantic Scholar
The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA
R. Suruki, J. Daugherty, N. Boudiaf, F. Albers
2017BMC Pulmonary Medicine240 citations Open access
Semantic Scholar
Biomarkers for severe eosinophilic asthma
S. Yancey, O. Keene, F. Albers, H. Ortega +3 more
2017Journal of Allergy and Clinical Immunology209 citations Open access
Semantic Scholar
Anti–IL‐5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
W. Busse, G. Chupp, H. Nagase, F. Albers +4 more
2019Journal of Allergy and Clinical Immunology198 citations Open access
Semantic Scholar
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
K. Chapman, F. Albers, B. Chipps, X. Muñoz +7 more
2019Allergy. European Journal of Allergy and Clinical Immunology150 citations Open access
Semantic Scholar
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
F. Albers, Hana Müllerová, N. Gunsoy, Ji-Yeon Shin +4 more
2018Journal of Asthma106 citations Open access
Semantic Scholar
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
A. Papi, B. Chipps, R. Beasley, R. Panettieri +8 more
2022New England Journal of Medicine94 citations Open access
Semantic Scholar
Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma.
H. Ortega, S. Yancey, O. Keene, N. Gunsoy +2 more
2018Journal of Allergy and Clinical Immunology: In Practice78 citations Open access
Semantic Scholar
Multinational cohort study of mortality in patients with asthma and severe asthma.
Marjolein Engelkes, M. D. de Ridder, E. Svensson, K. Berencsi +13 more
2020Respiratory Medicine70 citations Open access
Semantic Scholar
Burden of systemic glucocorticoid-related complications in severe asthma
P. Lefebvre, M. Duh, M. Lafeuille, L. Gozalo +8 more
2017Current Medical Research and Opinion66 citations
Semantic Scholar
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
F. Albers, C. Licskai, P. Chanez, D. Bratton +4 more
2019Respiratory Medicine61 citations Open access
Semantic Scholar
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sino-nasal and asthma outcomes with mepolizumab therapy.
P. Howarth, G. Chupp, L. Nelsen, E. Bradford +5 more
2020Journal of Allergy and Clinical Immunology56 citations Open access
Semantic Scholar
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
S. Cockle, G. Stynes, N. Gunsoy, D. Parks +5 more
2017Respiratory Medicine52 citations Open access
Semantic Scholar
Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
F. Albers, A. Papi, C. Taillé, D. Bratton +3 more
2019Respiratory Research49 citations Open access
Semantic Scholar
Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
C. Prazma, E. Bel, R. Price, E. Bradford +2 more
2019Respiratory Research47 citations Open access
Semantic Scholar
Incidence, risk factors and re‐exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study
Marjolein Engelkes, E. Baan, M. D. de Ridder, E. Svensson +15 more
2019Pediatric Allergy and Immunology38 citations Open access
Semantic Scholar
Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
H. Ortega, C. Lemière, J. Llanos, M. Forshag +4 more
2019Allergy, Asthma & Clinical Immunology37 citations Open access
Semantic Scholar
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
M. Liu, B. Chipps, X. Muñoz, G. Devouassoux +8 more
2021Respiratory Research35 citations Open access
Semantic Scholar
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
M. Humbert, F. Albers, D. Bratton, S. Yancey +4 more
2019Respiratory Medicine33 citations Open access
Semantic Scholar
Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study
Hana Müllerová, S. Cockle, N. Gunsoy, L. Nelsen +1 more
2019Journal of Asthma29 citations Open access
Semantic Scholar
Qualitative evaluation of the St George's Respiratory Questionnaire in patients with severe asthma.
L. Nelsen, M. Kimel, L. Murray, H. Ortega +5 more
2017Respiratory Medicine29 citations Open access
Semantic Scholar
Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
C. Lemière, C. Taillé, Jason K. Lee, Steven G. Smith +5 more
2021Respiratory Research27 citations Open access
Semantic Scholar
Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma
B. Chipps, E. Israel, R. Beasley, R. Panettieri +7 more
2023Chest21 citations
Semantic Scholar
Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
N. Gunsoy, S. Cockle, S. Yancey, O. Keene +3 more
2017Journal of Allergy and Clinical Immunology: In Practice21 citations Open access
Semantic Scholar
Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
P. Howarth, S. Quirce, A. Papi, E. Israel +5 more
2020Allergy. European Journal of Allergy and Clinical Immunology20 citations Open access
Semantic Scholar
Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
H. Ortega, A. Menzies-Gow, J. Llanos, M. Forshag +5 more
2018Advances in Therapy20 citations Open access
Semantic Scholar
Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
F. Albers, R. Price, Steven G. Smith, S. Yancey
2017Journal of Allergy and Clinical Immunology18 citations Open access
Semantic Scholar
Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
A. Wardlaw, P. Howarth, E. Israel, C. Taillé +5 more
2020Clinical and Experimental Allergy17 citations Open access
Semantic Scholar
Factors that affect blood eosinophil counts in a non-asthmatic population: Post hoc analysis of data from Brazil
N. Kwon, E. Pizzichini, A. Bansal, F. Albers +5 more
2020The World Allergy Organization Journal16 citations Open access
Semantic Scholar
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
B. Chipps, F. Albers, Laurence Reilly, E. Johnsson +2 more
2021BMJ Open Respiratory Research14 citations Open access
Semantic Scholar
Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes
Dmitry Galkin, M. Liu, B. Chipps, K. Chapman +6 more
201814 citations Open access
Semantic Scholar
Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma
F. Albers, D. Bratton, N. Gunsoy, S. Cockle +2 more
2022Clinical Respiratory Journal13 citations Open access
Semantic Scholar
Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
F. Albers, S. Hozawa, D. Bratton, S. Yancey +3 more
2019Allergy. European Journal of Allergy and Clinical Immunology13 citations Open access
Semantic Scholar
Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma.
L. Nelsen, M. Vernon, H. Ortega, S. Cockle +4 more
2017Respiratory Medicine13 citations Open access
Semantic Scholar
Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: the TYREE study.
C. Laforce, B. Chipps, F. Albers, Laurence Reilly +5 more
2021Annals of Allergy, Asthma & Immunology12 citations
Semantic Scholar
Effectiveness and safety of mepolizumab in real-world clinical practice: The REALITI-A study
Tim Harrison, G. Canonica, K. Gemzoe, A. Maxwell +6 more
2020Pneumologie11 citations
Semantic Scholar
Clinical burden of illness among patients with severe eosinophilic COPD
Hana Müllerová, W. Meeraus, Dmitry Galkin, F. Albers +1 more
2019International Journal of COPD11 citations Open access
Semantic Scholar
Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
C. Prazma, M. Idzko, J. Douglass, A. Bourdin +3 more
2021Journal of Asthma and Allergy10 citations Open access
Semantic Scholar
Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Mi-kyeong Kim, Hae-Sim Park, Choon-Sik Park, Soung-Jun Min +4 more
2020The Korean Journal of Internal Medicine9 citations Open access
Semantic Scholar
Impact of exacerbations on St George’s Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study
L. Nelsen, S. Cockle, N. Gunsoy, P. Jones +3 more
2020Journal of Asthma8 citations Open access
Semantic Scholar
Mepolizumab improves patient outcomes and reduces exacerbations in severe asthma patients with comorbid upper airways disease: 283
C. Prazma, F. Albers, S. Mallett, J. Llanos-Ackert +1 more
2019Journal of Allergy and Clinical Immunology8 citations Open access
Semantic Scholar
Update on immunogenicity in severe asthma: Experience with mepolizumab.
H. Ortega, E. Meyer, G. Brusselle, K. Asano +5 more
2019Journal of Allergy and Clinical Immunology: In Practice7 citations Open access
Semantic Scholar
Response to mepolizumab treatment is sustained across 4-weekly dosing periods
I. Pavord, E. Bleecker, R. Buhl, P. Chanez +5 more
2020ERJ Open Research6 citations Open access
Semantic Scholar
Association of depressive symptoms with health status and markers of uncontrolled severe asthma.
S. Khurana, J. Lyness, S. Mallett, L. Nelsen +6 more
2019Allergy and Asthma Proceedings5 citations
Semantic Scholar
Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma
L. Nelsen, E. Bradford, D. Bratton, F. Albers +1 more
20175 citations
Semantic Scholar
Efficacy Of Mepolizumab In Patients With Severe Eosinophilic Asthma And Nasal Polyps
M. Liu, O. Keene, S. Yancey, D. Bratton +1 more
20175 citations Open access
Semantic Scholar
BASELINE PERCENT PREDICTED FEV1 DOES NOT PREDICT A RESPONSE TO MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA: META-ANALYSIS FROM TWO PHASE 3 TRIALS
J. Silver, A. Menzies-Gow, Steven G. Smith, S. Mallett +3 more
2019Chest4 citations Open access
Semantic Scholar
Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration: 307
F. Albers, M. Liu, B. Chipps, K. Chapman +6 more
2019Journal of Allergy and Clinical Immunology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Yancey×26
Invite
S. Yancey — researcher profile on SciRah
E. Bradford×17
Invite
E. Bradford — researcher profile on SciRah
D. Bratton×11
Invite
D. Bratton — researcher profile on SciRah
H. Ortega×10
Invite
H. Ortega — researcher profile on SciRah

×10

Invite

S. Cockle — researcher profile on SciRah

Invite

L. Nelsen — researcher profile on SciRah

Invite

N. Gunsoy — researcher profile on SciRah

Invite

B. Chipps — researcher profile on SciRah

Invite

M. Liu — researcher profile on SciRah

Invite

N. Kwon — researcher profile on SciRah

Invite

S. Mallett — researcher profile on SciRah

Invite

R. Price — researcher profile on SciRah